Research programme: AAV/ZFP TF pain therapy - Avigen/Sangamo TherapeuticsAlternative Names: AAV/ZFP TF
Latest Information Update: 11 Jan 2017
At a glance
- Originator Avigen; Sangamo BioSciences
- Mechanism of Action Genetic transcription inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain